What’s hot in diabetes nursing? October 2025

Medicines

Rybelsus® (oral semaglutide): risk of medication error

Direct Healthcare Professional Communication from manufacturer. Risk of medication error due to introduction of new formulation with increased bioavailability.

(Source: Novo Nordisk)

Learning and events

ABCD DTN-UK Meeting 2025 and ABCD Conference 2025

For HCPs interested in the latest advances in diabetes technology. Followed by the annual ABCD conference. (Newcastle, 6 and 7 November).

(Source: Association of British Clinical Diabetologists)

Advancing equity in diabetes care for Black populations

In-person networking, expert-led sessions and learning for healthcare professionals and others (London, 26 November).

(Source: Diabetes Africa)

Diabetes in Pregnancy UK Conference 2025

One-day programme and registration now available (online, Tues. 11 November).

(Source: Diabetes UK)

Diabetes UK Professional Conference 2026

Register your interest in next year’s conference in Liverpool (22–24 April).

(Source: Diabetes UK)

World Diabetes Day

Get involved in raising awareness of the challenges of diabetes and prioritising well-being in the workplace.

(Source: International Diabetes Federation)

Guidelines, reports and position statements

Type 2 diabetes in adults: management (medicines update)

New draft guidance made available by NICE for consultation.

(Source: NICE)

Tackling Diabetes Stigma: position statement

Includes evidence-based recommendations to tackle negative attitudes and beliefs.

(Source: Diabetes UK)

Health trends and variation in England 2025: a CMO report

An overview of the health of England’s population.

(Source: Department of Health and Social Care)

Journals: Quick reads

Contraceptive considerations in people with type 2 diabetes

What to consider when discussing contraception with women living with type 2 diabetes. [Open access]

(Source: Diabetes & Primary Care)

Framework for the pharmacological treatment of obesity and its complications from the EASO

Overview of the present situation. Includes a treatment algorithm for individuals with obesity. [Open access]

(Source: Nature Medicine)

Coded and uncoded chronic kidney disease: an explainer

The pitfalls of coding ambiguities and their impact on patient outcomes. [Open access]

(Source: British Journal of General Practice)

Journals: Articles

Impact of baseline GLP-1 RA use on albuminuria reduction and safety with simultaneous initiation of finerenone and empagliflozin in type 2 diabetes and CKD

CONFIDENCE trial results support the benefits of combination therapy with finerenone and SGLT2is, regardless of baseline GLP-1 RA use. [Open access]

(Source: Diabetes Care)

Real-world titration, persistence and weight loss of semaglutide and tirzepatide in an academic obesity clinic

Difficulties optimising doses persist even in specialised settings. [Open access]

(Source: Diabetes, Obesity and Metabolism)

Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?

Review of the potential benefits of GLP-1 RAs in type 1 diabetes. [Open access]

(Source: Frontiers in Endocrinology)

From surviving to thriving: How sleep, physical activity, and diet shape well-being in young adults

Study underscores the importance of the “big three” health behaviours in well-being among young adults. [Open access]

(Source: PLoS One)

Plant-based dietary patterns and age-specific risk of multimorbidity of cancer and cardiometabolic diseases: a prospective analysis

A healthy plant-based diet may reduce disease burden in middle-aged and older adults. [Open access]

(Source: The Lancet Healthy Longevity)

Glycaemic control in women with type 1 diabetes and preeclampsia risk: a nationwide cohort study

Poorer peri-conceptional glycaemic control increases preeclampsia risk. [Open access]

(Source: BJOG)

Prescription distribution and inequities in diabetes care: A comparative analysis of CGM access by diabetes status, ethnicity and socio-economic factors in England

Significant CGM prescribing disparities exist, with Afro-Caribbean and South Asian populations receiving fewer prescriptions. [Open access]

(Source: Diabetic Medicine)

Global inequities in diabetes technology and insulin access and glycemic outcomes

Stark disparities underscore the urgent need for collective action. [Open access]

(Source: JAMA Network Open)

Global, regional, and national cascades of diabetes care, 2000–23: a systematic review and modelling analysis using findings from the Global Burden of Disease Study

Underdiagnosis and suboptimal glycaemic management remain major challenges globally.

(Source: The Lancet Diabetes & Endocrinology)

Dapagliflozin in patients hospitalized for heart failure: Primary results of the DAPA ACT HF-TIMI 68 randomized clinical trial and meta-analysis of SGLT-2 inhibitors in patients hospitalized for heart failure

The effects of in-hospital initiation of dapagliflozin on cardiovascular death or heart failure worsening. [Open access]

(Source: Circulation)

Risk differences and underlying factors of cardiovascular events and mortality in patients with type 2 diabetes versus type 1 diabetes

Insights from a longitudinal cohort study of Swedish nationwide register data.

(Source: The Lancet Diabetes & Endocrinology)